tRNA Metabolism in Neurodegeneration

tRNA Metabolism in Neurodegeneration

Transfer RNA (tRNA) molecules are essential adapters that decode messenger RNA (mRNA) into protein during translation. Beyond their canonical role in protein synthesis, tRNAs and their derived fragments (tRFs) have emerged as critical regulators of neuronal health and disease. Dysregulation of tRNA metabolism contributes to proteostasis collapse, translational impairment, and cellular stress responses observed in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

Overview of tRNA Biology

tRNA Processing and Disease Mechanisms

tRNA Metabolism in Neurodegeneration

Transfer RNA (tRNA) molecules are essential adapters that decode messenger RNA (mRNA) into protein during translation. Beyond their canonical role in protein synthesis, tRNAs and their derived fragments (tRFs) have emerged as critical regulators of neuronal health and disease. Dysregulation of tRNA metabolism contributes to proteostasis collapse, translational impairment, and cellular stress responses observed in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

Overview of tRNA Biology

tRNA Processing and Disease Mechanisms

This diagram illustrates tRNA biosynthesis steps and how defects in various processing stages contribute to neurodegenerative diseases through impaired protein translation.

tRNAs are ~76 nucleotide RNA molecules that carry specific amino acids to the ribosome during translation. Each tRNA contains an anticodon loop that base-pairs with mRNA codons and a 3' terminal CCA tail where the amino acid is attached. The human genome encodes ~500 tRNA genes and numerous tRNA-derived fragments["@chan2020"].

Key Components

• Aminoacyl-tRNA synthetases (ARS): Enzymes that charge tRNAs with their cognate amino acids. Mutations in several ARS genes cause familial ALS and peripheral neuropathies[@tsai2021].
• tRNA modifications: Over 100 post-transcriptional modifications modulate tRNA structure, stability, and function. Key modifications include pseudouridylation, methylation, and thiolation[@suzuki2021].
• tRNA-derived fragments (tRFs): Small RNAs (14-50 nucleotides) generated from tRNA precursors or mature tRNAs through specific cleavage pathways. tRFs regulate translation, transcription, and RNA silencing[@anderson2018].

Mechanisms of tRNA Dysregulation in Neurodegeneration

Translational Impairment

Neurodegenerative diseases exhibit profound defects in protein synthesis. Ribosome profiling studies reveal widespread changes in translation efficiency in affected brain regions, with particular impact on long transcripts encoding synaptic proteins and mitochondrial components[@jan2022].

Key mechanisms include:

tRNA-Derived Fragments (tRFs)

tRFs are generated through two main pathways:

• tRF-5: Derived from the 5' end of mature tRNAs, typically 18-22 nucleotides. These often function in translation repression.
• tRF-3: Derived from the 3' end, including the CCA tail. These can compete with full-length tRNAs for aminoacylation.
• tiRNAs: Cleavage products from the anticodon loop (tRNA halves), generated under stress by angiogenin. tiRNAs can inhibit protein synthesis and promote stress granule formation[@emara2010].

Aminoacyl-tRNA Synthetase Deficiencies

Mutations in ARS genes cause inherited neuropathies andALS. Notable examples include:

• HARS1/HARS2: Histidyl-tRNA synthetase mutations cause axonal Charcot-Marie-Tooth disease and hearing loss[@antonellis2023].
• KARS1: Lysyl-tRNA synthetase mutations cause intermediate Charcot-Marie-Tooth disease and hearing loss.
• AARS1: Alanyl-tRNA synthetase mutations cause dominant and recessive Charcot-Marie-Tooth disease.

Disease-Specific Mechanisms

Alzheimer's Disease

Translational dysregulation is an early feature of AD, preceding clinical symptoms. Ribosome profiling of AD brain tissue reveals reduced translation of synaptic proteins and mitochondrial components[@beckelman2021].

• tRNA modification changes: NSUN2 expression is reduced in AD [hippocampus](/brain-regions/hippocampus), leading to loss of tRNA modifications and translational impairment[@filonava2020].
• tRF accumulation: Specific tRFs (tRF-5-GlyGCC, tRF-5-ProTGG) are elevated in AD brain and CSF, potentially serving as biomarkers[@drago2021].
• Angiogenin activation: Stress-induced angiogenin cleavage of tRNAs generates tiRNAs that suppress global translation while promoting stress granule formation[@yu2019].

Parkinson's Disease

PD and related disorders show particular vulnerability of dopaminergic [neurons](/entities/neurons) to translational stress.

• Mitochondrial tRNA modifications: Mitochondrial tRNAs have unique modifications essential for proper translation of the 13 mitochondrial-encoded proteins. Mutations in mitochondrial tRNA genes (e.g., m.3243A>G) cause PD phenotypes[@pickrell2021].
• tRF-3 accumulation: Specific tRFs are elevated in PD substantia nigra and may contribute to [α-synuclein](/proteins/alpha-synuclein) aggregation pathology[@kadri2022].
• Translation stress response: Chronic translational impairment activates integrated stress response (ISR) pathways in PD models[@kim2020].

Amyotrophic Lateral Sclerosis (ALS) and FTD

ALS/FTD features translational dysregulation as a central pathogenic mechanism.

• tRNA modifications: Loss of NSUN2 and other tRNA modification enzymes contributes to translational defects in ALS models[@ito2021].
• tRFs in stress granules: tRFs are enriched in stress granules, membrane-less organelles that form under proteostasis stress and are dysregulated in ALS/FTD[@wolozin2019].
• [C9orf72](/entities/c9orf72) hexanucleotide expansion: The most common genetic cause of familial ALS/FTD produces dipeptide repeat proteins that disrupt nucleocytoplasmic transport and may impair tRNA processing[@boivin2020].

Therapeutic Implications

Targeting tRNA Metabolism

Biomarker Potential

tRFs show promise as diagnostic and prognostic biomarkers:

• CSF tRFs: Minimally invasive detection of disease-specific tRF signatures.
• Blood tRFs: Peripheral biomarkers with potential for disease monitoring.
• tRF ratios: Specific tRF ratios may indicate disease stage or progression.

Research Gaps and Future Directions

• Comprehensive tRF atlas: Systematic cataloging of tRFs in neurodegenerative diseases.
• Mechanistic studies: Functional validation of specific tRFs in models.
• Therapeutic development: High-throughput screening for modulators of tRNA metabolism.
• Biomarker validation: Large cohort studies to validate tRF signatures.
• Combination therapies: Targeting tRNA metabolism alongside other disease mechanisms.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

• [J et al. 2024: Prediction of Future Parkinson Disease Using Plasma Proteins Combined ](https://pubmed.ncbi.nlm.nih.gov/38976826/)
• [S et al. 2024: HSP70 binds to specific non-coding RNA and regulates human RNA polymer](https://pubmed.ncbi.nlm.nih.gov/38266641/)
• [J et al. 2025: Targeting tRNA-Derived Non-Coding RNA Alleviates Diabetes-Induced Visu](https://pubmed.ncbi.nlm.nih.gov/39513253/)
• [PK et al. 2025: Disruption of G3BP1 granules promotes mammalian CNS and PNS axon regen](https://pubmed.ncbi.nlm.nih.gov/40014573/)
• [M et al. 2024: The Yin and Yang of Microglia-Derived Extracellular Vesicles in CNS In](https://pubmed.ncbi.nlm.nih.gov/39594583/)

References